Breaking Down PerkinElmer, Inc. Financial Health: Key Insights for Investors

Delve into PerkinElmer, Inc.'s financial pulse with hard facts: trailing twelve months revenue sits at $3.35 billion as of November 2025 (down from $3.94B in 2022 and $5.06B in 2021) while last‑year revenue growth was about 3% and the 10‑year CAGR about 2%; Q1 2025 revenue was $665 million with 4% organic growth and a 1% FX headwind producing adjusted EPS of $1.01 (+$0.07 vs. expectations), Q3 2025 revenue reached $699M (vs. $684M year‑ago) with a 1.5% FX headwind and adjusted EPS of $1.18 (+$0.50 vs. midpoint), operating margin stands at 10.86% with ROE 12.71% and ROA 3.81%, operating cash flow of $811.32M and free cash flow of $722.03M (FCF/share $5.76; FCF yield 4.68%), net debt/adjusted EBITDA is 2.4x with 100% fixed‑rate debt at a 2.6% weighted average rate, active buybacks included $154M in Q1 and ~$205M (2.3M shares) in Q3 bringing total repurchases to 12.5M shares (~10% of outstanding) and a new $1B repurchase authorization, liquidity metrics show 97% FCF conversion in Q1 and adjusted operating margins of 25.6% (Q1) and 26.1% (Q3) with Q3 FCF of $120M (~90% of adjusted net income) and an adjusted Q1 tax rate of 19.5%, valuation reads P/E 46.21, P/B 3.2 and PEG -1.35, risks include recurring FX headwinds and debt maturities tied to prior acquisition financing, while growth pockets include 20% organic software growth in Q3, mid‑ to high‑single digit gains in reproductive health and newborn screening, a new neo LSD seven‑plex IVDR approval in Europe pending FDA clearance, and a sustainability target to cut Scope 1 and 2 emissions by 50.4% by 2032-read on for detailed implications for investors.

PerkinElmer, Inc. (0KHE.L) - Revenue Analysis

• TTM revenue (Nov 2025): $3.35 billion USD - down from $3.94 billion in 2022 and $5.06 billion in 2021.
• Revenue growth: ~3% year-over-year (last 12 months); 10-year CAGR ≈ 2%; negative trends over the past 3- and 5-year periods.
• Q1 2025 revenue: $665 million - 4% organic growth, ~1% FX headwind, zero incremental contribution from acquisitions.
• Q1 2025 adjusted EPS: $1.01, $0.07 above expectations (FX headwind noted).
• Q3 2025 revenue: $699 million vs. $684 million year-ago - positive year-over-year growth.
• Q3 2025 FX impact: ~1.5% headwind; adjusted EPS: $1.18, $0.50 above midpoint of guidance.

• FX headwinds: Consistent modest negative impact (~1%-1.5%) in reported quarters (Q1 and Q3 2025).
• Organic growth: Positive in reported quarters (Q1 4% organic), indicating core demand resilience absent acquisitions.
• Acquisition contribution: No incremental lift in Q1 2025; implies recent growth has been largely organic.
• EPS outperformance: Both Q1 and Q3 2025 adjusted EPS beat expectations, supporting operational margin or cost management offsets to revenue headwinds.

PerkinElmer, Inc. (0KHE.L) - Profitability Metrics

• Operating margin: 10.86% - indicates profit generated from core operations after operating expenses.
• Return on equity (ROE): 12.71% - reflects the company's efficiency in generating returns on shareholders' equity.
• Return on assets (ROA): 3.81% - shows how effectively assets are used to produce net income.

• Operating cash flow of $811.32M supports capital allocation flexibility without relying on external financing.
• Free cash flow of $722.03M and FCF/share $5.76 (yield 4.68%) provide a cushion for shareholder returns and strategic investments.
• ROE of 12.71% suggests management is delivering mid-teens returns on equity, while ROA of 3.81% reflects the capital intensity of PerkinElmer's asset base.

PerkinElmer, Inc. (0KHE.L) - Debt vs. Equity Structure

• Net debt to adjusted EBITDA: 2.4x - a leverage level reflecting the company's debt relative to operating cash generation.
• Debt coupon profile: 100% fixed-rate debt; weighted average interest rate ~2.6%.
• Debt maturity horizon: weighted average maturities extending roughly seven years.

• Capital deployment priorities:
  • Share repurchases (new $1B authorization)
  • Acquisitions funded historically with debt proceeds
  • Operational reinvestment and working capital
• Buyback scale: 12.5 million shares repurchased to date - roughly 10% of shares outstanding at year-end 2023, signaling a priority on shareholder returns.
• Recent repurchase cadence: $154M in Q1 2025 and ~$205M (2.3M shares) in Q3 2025.

PerkinElmer, Inc. (0KHE.L) - Liquidity and Solvency

• Free cash flow conversion: 97% in Q1 2025, signaling near-complete conversion of net income into cash.
• Adjusted operating margin: 25.6% in Q1 2025, reflecting tight expense control and favorable product/service mix.
• Adjusted tax rate: 19.5% in Q1 2025, improved by tax planning initiatives and below consensus expectations.

• Q3 2025 free cash flow: $120 million, approximately 90% of adjusted net income - comfortably above longer-term expectations.
• Q3 2025 adjusted operating margin: 26.1%, modestly exceeding expectations and up from Q1's 25.6%.
• Q3 2025 adjusted EPS: $1.18, which was $0.50 above the midpoint of guidance, underscoring operating leverage and cost discipline.

• High FCF conversion and consistent free cash generation reduce refinancing risk and support deleveraging or targeted capital allocation.
• Margins north of 25% provide buffer against revenue volatility and increase interest coverage potential.
• A lower effective tax rate improves net income retention and strengthens cash available for debt amortization or strategic investment.

PerkinElmer, Inc. (0KHE.L) - Valuation Analysis

• P/E ratio: 46.21 vs. benchmark 25 - significantly above market norm, implying high expectations priced into earnings.
• P/B ratio: 3.2 - market values equity at over three times book value.
• PEG ratio: -1.35 - negative PEG reflects either recent earnings declines or unusual growth/earnings dynamics; interpreted as potential undervaluation relative to growth when context is favorable.
• Free cash flow yield: 4.68% - moderate cash return relative to enterprise value/equity price.
• Free cash flow per share: $5.76 - direct per-share cash generation metric for shareholder value assessment.
• Operating margin: 10.86% - indicates core operating profitability level.

• A P/E of 46.21 signals market expectations of future growth; downside risk exists if growth disappoints.
• P/B of 3.2 suggests investors pay a premium for intangible assets, brand, or expected returns above book value.
• Negative PEG (-1.35) requires digging into recent EPS trends and growth forecasts to reconcile apparent undervaluation signal with high P/E.
• FCF yield (4.68%) and FCF per share ($5.76) provide tangible cash-based valuation support that can offset part of multiple-driven premium.
• Operating margin (10.86%) reflects operational strength but should be compared to peers in diagnostics/life-science tools for relative assessment.

PerkinElmer, Inc. (0KHE.L) - Risk Factors

• Foreign exchange (FX) volatility: reported FX headwinds were approximately 1% in Q1 2025 and ~1.5% in Q4 2024, reducing reported revenue and EPS vs. constant-currency results.
• Interest-rate exposure: weighted average interest rate on fixed-rate debt is 2.6%, creating sensitivity to refinancing costs if market rates rise materially before maturities are addressed.
• Debt maturity profile: scheduled maturities extend seven years out with notable buckets in 2023, 2024, 2028, and 2031, implying refinancing/refund needs that could pressure liquidity during adverse markets.
• Acquisition/divestiture risk: prior debt issuance (September 2021) to fund acquisitions increased leverage and integration execution risk; future M&A or disposals could alter capital structure and covenant headroom.
• Share repurchases: ongoing buyback programs can reduce available cash and flexibility to service debt or invest for growth, particularly if executed during weaker revenue periods.
• Regulatory & ESG compliance: commitments and evolving rules across jurisdictions expose the company to compliance costs, remediation expenses, and potential reputational risk that can affect commercial performance.

• Liquidity & refinancing considerations: with multi-year maturities and a 2.6% weighted fixed rate, PerkinElmer must balance refinancing timing against market rates and covenant constraints to avoid margin erosion.
• Operational sensitivity to FX: a recurring 1-1.5% reported FX drag can translate to meaningful EPS variance; hedging effectiveness and geographic revenue mix are key mitigants.
• M&A and capital allocation trade-offs: acquisition funding in 2021 increased leverage; management choices on buybacks versus deleveraging will directly affect credit metrics (net leverage, interest coverage).
• Regulatory risk management: investment in ESG compliance and environmental controls is necessary but may raise near-term capex and operating costs.

PerkinElmer, Inc. (0KHE.L) - Growth Opportunities

• Signals software business: organic growth of 20% in Q3 2025, reflecting strong demand for laboratory informatics and data solutions.
• Reproductive health portfolio: mid-single-digit year-over-year growth in Q3 2025; newborn screening up in the high single digits.
• Product pipeline expansion: neo LSD seven plex kit received IVDR approval in Europe and is currently awaiting FDA clearance, broadening the diagnostics addressable market.
• Capital allocation: board authorized a new $1 billion share repurchase program, signaling confidence in long-term value creation.
• Strategic investment posture: plans to step up internal investments in 2025, prioritizing high-return R&D and commercial initiatives.
• Sustainability target: committed to reduce Scope 1 and 2 emissions by 50.4% by 2032, aligning operations with ESG-driven customer and investor preferences.